Less than a week into 2020 and NICE has provisionally ruled against NHS funding for another drug – in this case Akcea’s ground-breaking antisense drug Waylivra (volanesorsen) for the ultra-
NICE has said in first draft guidance that Roche’s Tecentriq should not get regular NHS funding as a treatment for a kind of advanced lung cancer, citing “highly uncertain” data about the d
